AP Gets First Notified Body for Medical Device Manufacturing Facilities Inspection

CDSCO has notified KIHT Certification Services (KCS) inside AMTZ as state’s first regulatory body

Visakhapatnam: Andhra Pradesh is now home to its first-ever CDSCO notified auditing body for medical devices. In a significant move, the Central Drugs Standard Control Organisation (CDSCO) under Minister of Health and Family Welfare, Govt. of India has notified KIHT Certification Services (KCS) as the state’s first regulatory body authorised to inspect manufacturing facilities for Class A and Class B medical devices.

Among 14 such notified bodies nationwide, KCS is the only one operational in Andhra Pradesh and Telangana, marking a milestone in the region’s quality management capabilities. Founded in July 2017, Kalam Institute of Health Technology (KIHT) housed inside the AMTZ campus is a Government of India project supported by the Department of Biotechnology, at promoting and supporting innovations in medical technologies through research and development, industry promotion, policy-making and knowledge repository.

Founded in April 2022, KCS is accredited by the National Accreditation Board for Certification Bodies (NABCB) under ISO/IEC 17021 1:2015 and IAF MD 9:2023 standards. The organisation offers comprehensive services including ISO 13485 certification, quality systems audits, risk management training, and CE mark consultancy—making it a full-service hub for manufacturers seeking to meet global regulatory standards.

This approval brings immediate benefits to domestic manufacturers, particularly MSMEs, by eliminating the need for audits outside the state—resulting in significant time and cost savings. It also reinforces Andhra Pradesh’s MedTech credentials, supporting national campaigns like “Make in India” and “ACI manufacturing,” while making the region highly attractive for future investments. This significant milestone empowers KCS to conduct independent regulatory audits for medical device manufacturers in accordance with the Medical Devices Rules (MDR) 2017 for Class A (low risk) and Class B (moderate risk), the state underscores its reputation as a business-friendly hub, ready to meet rising global demand in healthcare.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states